ReviewDiagnostics (Basel, Switzerland)2022
Non-Gestational Ovarian Choriocarcinoma: A Rare Ovarian Cancer Subtype.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- An extremely rare primary non-gestational choriocarcinoma of the vagina: a case report.Annals of medicine and surgery (2012) · 2025Article
- Rare occurrence of ovarian choriocarcinoma: ultrasound evaluation.Journal of ultrasound · 2025Article
- Clinical and Imaging Characteristics of Non-Gestational Ovarian Choriocarcinoma: A Case Report.Current medical imaging · 2025Article
- A rare case of pure non-gestational ovarian choriocarcinoma: Diagnostic mimicry and management strategies.Oncoscience · 2025Article
- Article
- Non-gestational Choriocarcinoma of the Ovary: A Report of a Rare Case From Saudi Arabia.Cureus · 2024Article
- Ovarian Germ Cell Tumors in North-Western India: A Comprehensive 3-Year Retrospective Study of 145 Cases at a Tertiary Cancer Hospital.Indian journal of surgical oncology · 2024Article
- Rapid recurrence of stage IIB non-gestational ovarian choriocarcinoma with minor yolk sac tumor: A rare case report and literature review.Gynecologic oncology reports · 2023Article
- Primary ovarian choriocarcinoma occurring in a postmenopausal woman: A case report.World journal of clinical cases · 2023Article
- Ultra-High-Risk Gestational Choriocarcinoma of the Ovary Associated with Ectopic Pregnancy.Current oncology (Toronto, Ont.) · 2023Review
- Choriocarcinoma complicated with intra-abdominal and intrapleural hemorrhage in pregnancy - case report.Frontiers in oncology · 2023Article
- Successful Management of Ultra-high-risk Mixed Ovarian Germ Cell Tumor Using a Pediatric-inspired Intensive Chemotherapy Regimen: A Case Report.In vivo (Athens, Greece)Article
- Primary Extragonadal Choriocarcinoma Presenting with Pneumothorax in an Elderly Male Patient: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-Gestational Ovarian Choriocarcinoma (NGOC) is an extremely rare ovarian tumor, with an incidence of less than 0.6% of malignant ovarian germ cell tumors. Its close pathologic resemblance to Gestational Ovarian Choriocarcinoma (GOC), however, requires special attention as the treatments differ greatly. NGOC typically affects patients in late adolescence or early reproductive years. As a result, NGOCs are often misdiagnosed as ectopic pregnancies due to their common presentation of bleeding, abdominal pain, adnexal mass, and positive serum beta-HCG. On pathologic examination, the tumor is indistinguishable from GOC, and only after review of tissue for paternal genetic components can the diagnosis of NGOC be made. Imaging studies often show highly vascular lesions with further investigation with computer topography (CT) sometimes showing metastatic lesions in the lungs, pelvis, vagina, and liver. These lesions are often hemorrhagic and can lead to catastrophic bleeding. Treatment is vastly different from GOC; NGOC requires treatment with both surgical resection and chemotherapy, with Bleomycin, Etoposide, and Cisplatin (BEP) being the most used regimen. With correct diagnosis and treatment, patients can often receive fertility sparing treatment with long term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.